These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30156128)

  • 1. Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
    Gagne JJ; Tsacogianis T; Bruce Wirta S; Rogers JR; Calado F; Chang CL; Turner SJ; Schlienger RG; Balas B; Abdurrob A; Najafzadeh M; Wang SV
    J Comp Eff Res; 2018 Nov; 7(11):1073-1082. PubMed ID: 30156128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
    Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
    Wachter R; Viriato D; Klebs S; Grunow SS; Schindler M; Engelhard J; Proenca CC; Calado F; Schlienger R; Dworak M; Balas B; Bruce Wirta S
    Postgrad Med; 2018 Apr; 130(3):308-316. PubMed ID: 29446691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction.
    Antol DD; Casebeer AW; DeClue RW; Stemkowski S; Russo PA
    Adv Ther; 2018 Jun; 35(6):785-795. PubMed ID: 29777521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
    Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
    Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-Related Quality of Life Outcomes in PARADIGM-HF.
    Lewis EF; Claggett BL; McMurray JJV; Packer M; Lefkowitz MP; Rouleau JL; Liu J; Shi VC; Zile MR; Desai AS; Solomon SD; Swedberg K
    Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28784687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.